|
|
DRUG INTERACTIONS
Drug Interactions:
Cabergoline should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.
|
OVERDOSAGE
Overdosage might be expected to produce nasal congestion, syncope, or hallucinations. Measures to support blood pressure should be taken if necessary.
|
CONTRAINDICATIONS
Cabergoline tablets are contraindicated in patients with
- Uncontrolled hypertension or known hypersensitivity to ergot derivatives.
- History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (See
WARNINGS).
- History of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (See
WARNINGS)
|
|
|
|
|
|
-- advertisement --
|
